{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T19:41:12Z","timestamp":1768678872871,"version":"3.49.0"},"reference-count":24,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,7,11]],"date-time":"2017-07-11T00:00:00Z","timestamp":1499731200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl J Gynecology & Obste"],"published-print":{"date-parts":[[2017,10]]},"abstract":"Abstract<\/jats:title>Objective<\/jats:title>To estimate the potential impact of the nonavalent HPV<\/jats:styled-content> vaccine for high\u2010grade cervical lesions and invasive cervical cancer (ICC<\/jats:styled-content>) in Portugal.<\/jats:p><\/jats:sec>Methods<\/jats:title>The present secondary analysis used data collected in the CLEOPATRE II<\/jats:styled-content> study on the prevalence of HPV<\/jats:styled-content> 6\/11\/16\/18\/31\/33\/45\/52\/58 among female patients aged 20\u201388\u00a0years. The prevalence of HPV<\/jats:styled-content> types in patients with cervical intraepithelial neoplasia (CIN<\/jats:styled-content>) grades 2\/3 and ICC<\/jats:styled-content> was examined.<\/jats:p><\/jats:sec>Results<\/jats:title>Data were included from 582 patients. There were 177, 341, and 64 patients with CIN<\/jats:styled-content>2, CIN<\/jats:styled-content>3, and ICC<\/jats:styled-content>, respectively, and 169 (95.5%), 339 (99.4%), and 62 (96.9) of them had HPV<\/jats:styled-content> infections. Of patients with HPV<\/jats:styled-content> infections, HPV<\/jats:styled-content> 16, 18, 31, 33, 45, 52, and 58 infections were identified in 150 (88.8%), 329 (97.1%), and 60 (96.8%) patients with CIN<\/jats:styled-content>2, CIN<\/jats:styled-content>3, and ICC<\/jats:styled-content>, respectively. HPV<\/jats:styled-content> genotypes 6, 11, 16, 18, 31, 33, 45, 52, and 58 were identified in 540 (94.7%) of the patients with HPV<\/jats:styled-content> infections.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>The addition of the five HPV<\/jats:styled-content> genotypes included in the nonavalent HPV<\/jats:styled-content> vaccine (HPV<\/jats:styled-content> 31\/33\/45\/52\/58) could result in the new HPV<\/jats:styled-content> vaccine preventing 94.7% of CIN<\/jats:styled-content>2\/3 and ICC<\/jats:styled-content> occurrences.<\/jats:p><\/jats:sec>","DOI":"10.1002\/ijgo.12243","type":"journal-article","created":{"date-parts":[[2017,6,20]],"date-time":"2017-06-20T18:27:26Z","timestamp":1497983246000},"page":"90-94","source":"Crossref","is-referenced-by-count":5,"title":["Potential impact of nonavalent HPV<\/scp> vaccine in the prevention of high\u2010grade cervical lesions and cervical cancer in Portugal"],"prefix":"10.1002","volume":"139","author":[{"given":"Angela","family":"Pista","sequence":"first","affiliation":[{"name":"Independent Researcher Lisbon Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos Freire","family":"de Oliveira","sequence":"additional","affiliation":[{"name":"Federation for the Gynecological and Obstetrician Societies Coimbra Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Lopes","sequence":"additional","affiliation":[{"name":"Abel Salazar Biomedical Sciences Institute Oporto Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria J.","family":"Cunha","sequence":"additional","affiliation":[{"name":"Scientific Department Sanofi Pasteur MSD\u2010Portugal Amadora Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the CLEOPATRE Portugal study group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,7,11]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.07.055"},{"key":"e_1_2_8_4_1","unstructured":"IARC Monographs on the evaluation on carcinogenic risk to humans: Vol 100 B a review of human carcinogens. Part B: Biological Agents Vol 100 [IARC Web site].2011.http:\/\/monographs.iarc.fr\/ENG\/Monographs\/vol100B\/mono100B-1.pdf. Accessed August 16 2015."},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.05.064"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70230-8"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-14-0410"},{"key":"e_1_2_8_8_1","unstructured":"FerlayJ SoerjomataramI ErvikM et\u00a0al.GLOBOCAN 2012 v1.0 Cancer Incidence and mortality worldwide: IARC CancerBase No. 11 [IARC Web site].2013.http:\/\/globocan.iarc.fr\/. Accessed August 16 2015."},{"key":"e_1_2_8_9_1","unstructured":"ICO Information Centre on HPV and Cancer [WHO Web site].2015.www.hpvcentre.net\/. Accessed August 16 2015."},{"key":"e_1_2_8_10_1","unstructured":"European Public Assessment Report (EPAR) for Cervarix. [EMA Web site].2007.http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000721\/human_med_000694.jsp&mid=WC0b01ac058001d124. Accessed July 24 2015."},{"key":"e_1_2_8_11_1","unstructured":"European Public Assessment Report (EPAR) for Gardasil. [EMA Web site].2006.http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000703\/human_med_000805.jsp. Accessed July 24 2015."},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f2032"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g1458"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw354"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71179-9"},{"key":"e_1_2_8_16_1","unstructured":"National Vaccination Program (NVP).Introduction of the vaccine against infection by the human papilloma virus \u2010 Regulatory Circular No. 22\/DSCS\/UCPD 2008. General Directory of Health Ministry of Health Portugal. [DGS Web site].https:\/\/www.dgs.pt\/paginas-de-sistema\/saude-de-a-a-z\/programa-nacional-de-vacinacao\/normas-e-orientacoes.aspx. Accessed August 16 2015."},{"key":"e_1_2_8_17_1","unstructured":"Vaccination Bulletin \u2010 Special Edition No. 8 April2014. General Directory of Health Ministry of Health Portugal. [DGS Web site].https:\/\/www.dgs.pt\/paginas-de-sistema\/saude-de-a-a-z\/programa-nacional-de-vacinacao\/boletim-vacinacao.aspx. Accessed August 16 2015."},{"key":"e_1_2_8_18_1","unstructured":"Vaccination Bulletin \u2010 Special Edition No. 10 2016General Directory of Health Ministry of Health Portugal. [DGS Web site].https:\/\/www.dgs.pt\/paginas-de-sistema\/saude-de-a-a-z\/programa-nacional-de-vacinacao\/boletim-vacinacao.aspx. Accessed August 16 2015."},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0b013e31821dd3b2"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0b013e318280f26e"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-9378-7-38"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.06.001"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pvr.2016.03.002"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pvr.2015.06.003"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.23712"}],"container-title":["International Journal of Gynecology & Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijgo.12243","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijgo.12243","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T22:02:06Z","timestamp":1696370526000},"score":1,"resource":{"primary":{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/10.1002\/ijgo.12243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,11]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["10.1002\/ijgo.12243"],"URL":"https:\/\/doi.org\/10.1002\/ijgo.12243","archive":["Portico"],"relation":{},"ISSN":["0020-7292","1879-3479"],"issn-type":[{"value":"0020-7292","type":"print"},{"value":"1879-3479","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,11]]}}}